| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:16079077 | IVTH | 25 - 100 mg/L | 25 - 100 mg/L | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations |
| IVTH | 25 - 100 mg/L | 25 - 100 mg/L | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:20021041 | IVR | 400 mg/L | 400 mg/L | Oxidative stress in liver | Hepatic endocrine-mediated perturbations |
| IVR | 400 mg/L | 400 mg/L | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 400 mg/L | 400 mg/L | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 400 mg/L | 400 mg/L | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 15 mg/kg | 15 mg/kg | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 15 mg/kg | 15 mg/kg | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 15 mg/kg | 15 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 15 mg/kg | 15 mg/kg | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/kg | 3 mg/kg | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 75 mg/kg | 75 mg/kg | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 75 mg/kg | 75 mg/kg | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 75 mg/kg | 75 mg/kg | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 75 mg/kg | 75 mg/kg | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Affects glucose metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| PMID:21783476 | IVR | 400 mg/L | 400 mg/L | Elevated glucose levels | Metabolic endocrine-mediated perturbations |
| IVR | 400 mg/L | 400 mg/L | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 400 mg/L | 400 mg/L | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/L | 200 mg/L | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Affects skeletal development | Developmental endocrine-mediated perturbations | |
| PMID:25429344 | IVR | 500 mg/kg | 500 mg/kg | Alters sperm function | Reproductive endocrine-mediated perturbations |
| IVR | 500 mg/kg | 500 mg/kg | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg | 500 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg | 500 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 500 mg/kg | 500 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| PMID:3996333 | IVR | 4000 mg/L | 4000 mg/L | Changes in liver morphology | Hepatic endocrine-mediated perturbations |
| IVR | 4000 mg/L | 4000 mg/L | Hyperplasia in parathyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 4700 mg/L | 4700 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 5000 mg/L | 5000 mg/L | Affects acetylcholinesterase activity | Neurological endocrine-mediated perturbations | |
| IVR | 100 mg/L | - | No significant effects observed | - | |
| IVR | 1000 mg/L | 1000 mg/L | Affects acetylcholinesterase activity | Neurological endocrine-mediated perturbations | |
| IVR | 8000 mg/L | 8000 mg/L | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 8000 mg/L | 8000 mg/L | Testicular atrophy | Reproductive endocrine-mediated perturbations | |
| IVR | 8150 mg/L | 8150 mg/L | Cancer phenotype | Endocrine-mediated cancer | |
| IVR | 2000 mg/L | 2000 mg/L | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 2000 mg/L | 2000 mg/L | Hyperplasia in parathyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 16000 mg/L | 16000 mg/L | Testicular atrophy | Reproductive endocrine-mediated perturbations | |
| IVR | 16000 mg/L | 16000 mg/L | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| PMID:8434444 | IVR | 10 mg/kg | 10 mg/kg | Increase in cortisol levels | Neurological endocrine-mediated perturbations |
| IVR | 100 mg/kg | 100 mg/kg | Increase in cortisol levels | Neurological endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.